Tyme Technologies, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven E. Hoffman
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17 State St Fl 7 New York City NY United States of America 07921
- IPO Date
- May 25, 2012
- CIK
- 0001537917
- Website
- tymeinc.com
- Similar Companies
- Business
- Tyme Technologies, Inc. (NASDAQ: TYME) develops cancer metabolism-based therapies (CMBTs) designed to target the unique metabolic vulnerabilities of cancer cells through mechanisms such as disrupting protein synthesis, increasing oxidative stress, inducing amino acid transport, modulating autophagy, and inhibiting key intracellular pathways; its lead investigational product, SM-88, an oral modified proprietary tyrosine derivative, is in Phase II/III clinical development for treatment across 15 cancer types including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon cancers, with preclinical candidates TYME-18 for inoperable tumors and TYME-19, an oral synthetic bile acid family member, originally for SARS-CoV-2 diseases. The company, founded in 2011 and headquartered in Bedminster, New Jersey, at 1 Pluckemin Way, Suite 103, previously known as Global Group Enterprises Corp., focuses on metastatic and hard-to-treat solid and hematological cancers where current therapies prove inadequate, serving patients and healthcare providers primarily in the United States through research collaborations including Mayo Clinic for pancreatic cancer analysis and Georgetown University for breast cancer studies. In recent developments, Tyme Technologies merged with Syros Pharmaceuticals in September 2022, operating thereafter as a subsidiary with Syros advancing the combined pipeline funded by approximately $240 million in cash resources extending into 2025, while continuing SM-88 development following the 2022 discontinuation of its combination arm in the Pancreatic Cancer Action Network's Precision Promise trial due to futility against standard chemotherapy.
Nubank Helps Digital Lender Tyme Reach $1.5 Billion Valuation
Brazilian digital lender Nubank invests $150 million in Tyme Group
Nubank Announces Investment in Tyme Group, a Digital Bank With Operations in South Africa and the Philippines
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger
SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
Tyme Technologies shares jump premarket on news board to explore strategic options
Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
Tyme Technologies Stock (TYME): Why The Price Fell
Tyme Technologies Offers Incredible Risk-Reward
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
Tyme Technologies: The Market Missed The Bullish Memo